Quick Take
Peloton Therapeutics (PLTX) intends to raise $150 million in an IPO of its common stock, per an amended registration statement.
The company is advancing a pipeline of small molecule therapeutic candidates for the treatment of kidney cancer and other diseases.
PLTX has had quite promising trial results for its lead program. The firm has a strong investor syndicate though the IPO is a bit pricey.
Company & Technology
Dallas, Texas-based Peloton was founded in 2010 to develop therapeutics for the treatment of cancer with an initial focus on the Hypoxia-inducible